|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ATP11A |
Gene summary for ATP11A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ATP11A | Gene ID | 23250 |
| Gene name | ATPase phospholipid transporting 11A | |
| Gene Alias | ATPIH | |
| Cytomap | 13q34 | |
| Gene Type | protein-coding | GO ID | GO:0001701 | UniProtAcc | P98196 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23250 | ATP11A | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.67e-02 | 2.75e-01 | -0.059 |
| 23250 | ATP11A | HTA11_99999970781_79442 | Human | Colorectum | MSS | 7.34e-04 | 3.37e-01 | 0.294 |
| 23250 | ATP11A | HTA11_99999965104_69814 | Human | Colorectum | MSS | 2.49e-24 | 1.07e+00 | 0.281 |
| 23250 | ATP11A | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.09e-47 | 1.47e+00 | 0.3859 |
| 23250 | ATP11A | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.92e-07 | 6.27e-01 | 0.2585 |
| 23250 | ATP11A | A015-C-203 | Human | Colorectum | FAP | 6.61e-07 | -1.82e-01 | -0.1294 |
| 23250 | ATP11A | A001-C-108 | Human | Colorectum | FAP | 3.41e-02 | 9.52e-02 | -0.0272 |
| 23250 | ATP11A | A002-C-205 | Human | Colorectum | FAP | 8.81e-03 | -1.11e-01 | -0.1236 |
| 23250 | ATP11A | A015-C-104 | Human | Colorectum | FAP | 4.47e-07 | -1.34e-01 | -0.1899 |
| 23250 | ATP11A | A002-C-016 | Human | Colorectum | FAP | 2.38e-02 | -8.45e-02 | 0.0521 |
| 23250 | ATP11A | A001-C-007 | Human | Colorectum | CRC | 4.73e-06 | 5.87e-01 | 0.1899 |
| 23250 | ATP11A | A002-C-116 | Human | Colorectum | FAP | 2.43e-06 | -1.42e-01 | -0.0452 |
| 23250 | ATP11A | A018-E-020 | Human | Colorectum | FAP | 5.12e-03 | -2.24e-01 | -0.2034 |
| 23250 | ATP11A | F034 | Human | Colorectum | FAP | 7.01e-03 | -1.88e-02 | -0.0665 |
| 23250 | ATP11A | CRC-1-8810 | Human | Colorectum | CRC | 2.83e-05 | 3.41e-01 | 0.6257 |
| 23250 | ATP11A | CRC-3-11773 | Human | Colorectum | CRC | 1.50e-03 | 3.40e-01 | 0.2564 |
| 23250 | ATP11A | AEH-subject1 | Human | Endometrium | AEH | 5.46e-18 | 5.58e-01 | -0.3059 |
| 23250 | ATP11A | AEH-subject2 | Human | Endometrium | AEH | 8.87e-04 | 3.74e-01 | -0.2525 |
| 23250 | ATP11A | AEH-subject3 | Human | Endometrium | AEH | 4.24e-08 | 3.64e-01 | -0.2576 |
| 23250 | ATP11A | AEH-subject4 | Human | Endometrium | AEH | 5.96e-06 | 4.56e-01 | -0.2657 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0001701 | Colorectum | AD | in utero embryonic development | 110/3918 | 367/18723 | 2.36e-05 | 4.62e-04 | 110 |
| GO:0010876 | Colorectum | AD | lipid localization | 120/3918 | 448/18723 | 1.59e-03 | 1.33e-02 | 120 |
| GO:0006869 | Colorectum | AD | lipid transport | 108/3918 | 398/18723 | 1.67e-03 | 1.39e-02 | 108 |
| GO:0015748 | Colorectum | AD | organophosphate ester transport | 42/3918 | 140/18723 | 7.04e-03 | 4.31e-02 | 42 |
| GO:00017012 | Colorectum | MSS | in utero embryonic development | 99/3467 | 367/18723 | 3.71e-05 | 7.10e-04 | 99 |
| GO:00108761 | Colorectum | MSS | lipid localization | 104/3467 | 448/18723 | 6.76e-03 | 4.38e-02 | 104 |
| GO:00017013 | Colorectum | FAP | in utero embryonic development | 81/2622 | 367/18723 | 1.58e-05 | 4.10e-04 | 81 |
| GO:00068691 | Colorectum | FAP | lipid transport | 81/2622 | 398/18723 | 2.84e-04 | 3.76e-03 | 81 |
| GO:00108762 | Colorectum | FAP | lipid localization | 85/2622 | 448/18723 | 1.92e-03 | 1.63e-02 | 85 |
| GO:0015914 | Colorectum | FAP | phospholipid transport | 23/2622 | 96/18723 | 6.09e-03 | 3.82e-02 | 23 |
| GO:00068692 | Colorectum | CRC | lipid transport | 63/2078 | 398/18723 | 2.36e-03 | 2.26e-02 | 63 |
| GO:00108763 | Colorectum | CRC | lipid localization | 68/2078 | 448/18723 | 4.60e-03 | 3.58e-02 | 68 |
| GO:00017014 | Colorectum | CRC | in utero embryonic development | 57/2078 | 367/18723 | 5.54e-03 | 4.19e-02 | 57 |
| GO:00017019 | Endometrium | AEH | in utero embryonic development | 73/2100 | 367/18723 | 7.18e-07 | 2.63e-05 | 73 |
| GO:00426925 | Endometrium | AEH | muscle cell differentiation | 68/2100 | 384/18723 | 8.88e-05 | 1.30e-03 | 68 |
| GO:00511465 | Endometrium | AEH | striated muscle cell differentiation | 51/2100 | 283/18723 | 4.20e-04 | 4.46e-03 | 51 |
| GO:000170114 | Endometrium | EEC | in utero embryonic development | 75/2168 | 367/18723 | 5.86e-07 | 2.16e-05 | 75 |
| GO:004269212 | Endometrium | EEC | muscle cell differentiation | 67/2168 | 384/18723 | 3.87e-04 | 4.12e-03 | 67 |
| GO:005114613 | Endometrium | EEC | striated muscle cell differentiation | 51/2168 | 283/18723 | 8.71e-04 | 7.97e-03 | 51 |
| GO:00108765 | Liver | NAFLD | lipid localization | 79/1882 | 448/18723 | 4.75e-07 | 2.92e-05 | 79 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ATP11A | SNV | Missense_Mutation | c.327N>G | p.Ile109Met | p.I109M | P98196 | protein_coding | deleterious(0) | benign(0.349) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ATP11A | SNV | Missense_Mutation | c.2552N>A | p.Ala851Asp | p.A851D | P98196 | protein_coding | deleterious(0) | possibly_damaging(0.883) | TCGA-BH-A0BW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | CR | |
| ATP11A | SNV | Missense_Mutation | novel | c.1930N>C | p.Glu644Gln | p.E644Q | P98196 | protein_coding | tolerated(0.25) | benign(0.127) | TCGA-BH-A209-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ATP11A | SNV | Missense_Mutation | novel | c.61N>A | p.Val21Met | p.V21M | P98196 | protein_coding | deleterious(0) | possibly_damaging(0.784) | TCGA-D8-A27R-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin+cyclophosphamide | SD |
| ATP11A | SNV | Missense_Mutation | rs779974601 | c.2507N>T | p.Ala836Val | p.A836V | P98196 | protein_coding | deleterious(0.01) | probably_damaging(0.992) | TCGA-E9-A248-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| ATP11A | SNV | Missense_Mutation | novel | c.2155N>C | p.Glu719Gln | p.E719Q | P98196 | protein_coding | tolerated(0.07) | possibly_damaging(0.593) | TCGA-PL-A8LV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| ATP11A | insertion | In_Frame_Ins | novel | c.2201_2202insGTCACACAGGCCTGGCATGTGGCAAGC | p.Val734_Leu735insSerHisArgProGlyMetTrpGlnAla | p.V734_L735insSHRPGMWQA | P98196 | protein_coding | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| ATP11A | insertion | Frame_Shift_Ins | novel | c.1138_1139insATGGCCACACCCCTCCTTCCTGCTCTTT | p.Thr380AsnfsTer17 | p.T380Nfs*17 | P98196 | protein_coding | TCGA-A8-A07Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Exemestane | SD | ||
| ATP11A | insertion | Frame_Shift_Ins | novel | c.1690_1691insGCACCAGCTGCACCCACTCCACAGCACCCTGGGC | p.Val564GlyfsTer40 | p.V564Gfs*40 | P98196 | protein_coding | TCGA-B6-A0IC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| ATP11A | insertion | Frame_Shift_Ins | novel | c.75_76insCCCGCCTTCT | p.Ile26ProfsTer45 | p.I26Pfs*45 | P98196 | protein_coding | TCGA-BH-A0HX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adrimycin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |